共济失调毛细血管扩张突变蛋白通过调控AKT/DRP1介导的线粒体稳态保护脂多糖诱导的血脑屏障破坏
本研究用LPS在体内诱导血脑屏障破坏并建立脑血管内皮细胞体外模型,通过伊文思蓝渗漏和血管通透性调节因子表达评估屏障破坏。ATM抑制剂AZD1390加重血脑屏障通透性及随后的神经炎症和神经元损伤,而多柔比星激活ATM可消除这些缺陷。机制上,ATM抑制降低DRP1丝氨酸637位点磷酸化、促进线粒体过度分裂和线粒体功能障碍;多柔比星激活ATM增加ATM与AKT结合并促进AKT S473磷酸化,直接磷酸化DRP1 S637以抑制过度线粒体分裂。AKT抑制剂MK-2206可取消ATM的保护作用。
要点
- LPS攻击可诱导显著的血脑屏障破坏、ATM激活和线粒体转位。
- ATM抑制剂AZD1390加重血脑屏障通透性以及随后的神经炎症和神经元损伤。
- 多柔比星激活ATM可消除LPS诱导的血脑屏障破坏、神经炎症和神经元损伤。
- ATM抑制降低DRP1 S637磷酸化、促进线粒体过度分裂并导致线粒体功能障碍。
- AKT抑制剂MK-2206可取消ATM的保护作用,提示保护至少部分经AKT/DRP1通路。
适用人群与场景
- LPS诱导血脑屏障破坏的体内模型及脑血管内皮细胞体外模型,用于研究脓毒症中ATM对血脑屏障功能的调控。
处置流程与药物剂量
- 体内和体外均用LPS诱导血脑屏障破坏。
- 为研究ATM作用,按计划给予ATM抑制剂AZD1390和临床已批准的可激活ATM的蒽环类药物多柔比星。
- 为探索机制,给予AKT抑制剂MK-2206阻断AKT/DRP1通路。
研究设计与关键结果
- LPS攻击诱导显著的血脑屏障破坏、ATM激活和线粒体转位。
- AZD1390抑制ATM加重血脑屏障通透性以及随后的神经炎症和神经元损伤;多柔比星激活ATM可消除这些缺陷。
- 脑微血管内皮细胞中,ATM抑制降低DRP1丝氨酸637位点磷酸化,促进线粒体过度分裂并导致线粒体功能障碍。
- 多柔比星激活ATM增加ATM与AKT的蛋白结合,促进AKT S473磷酸化激活,后者可直接磷酸化DRP1 S637以抑制过度线粒体分裂。
- AKT抑制剂MK-2206可取消ATM的保护作用。
证据类型、等级与局限
- 基础实验研究(体内LPS模型与体外脑血管内皮细胞模型)。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,ATM通过调控线粒体稳态、至少部分经AKT/DRP1通路,保护LPS诱导的血脑屏障破坏。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Protein kinase ataxia telangiectasia mutated (ATM) regulates the function of endothelial cells and responds quickly to endotoxin. However, the function of ATM in lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) disruption remains unknown. This study aimed to investigate the role and underlying mechanism of ATM in the regulation of the BBB function in sepsis. Methods: We used LPS to induce BBB disruption in vivo and to establish an in vitro model of cerebrovascular endothelial cells. Blood-brain barrier disruption was assessed by measuring Evans blue leakage and expression of vascular permeability regulators. To investigate the role of ATM, its inhibitor AZD1390 and clinically approved doxorubicin, an anthracycline that can activate ATM, were administered as scheduled. To explore the underlying mechanism, protein kinase B (AKT) inhibitor MK-2206 was administered to block the AKT/dynamin-related protein 1 (DRP1) pathway. Results: Lipopolysaccharide challenge induced significant BBB disruption, ATM activation, and mitochondrial translocation. Inhibiting ATM with AZD1390 aggravated BBB permeability as well as the following neuroinflammation and neuronal injury, while activation of ATM by doxorubicin abrogated these defects. Further results obtained in brain microvascular endothelial cells showed that ATM inhibition reduced the phosphorylation of DRP1 at serine (S) 637, promoted excessive mitochondrial fission, and resulted in mitochondrial malfunction. By activating ATM, doxorubicin increased the protein binding between ATM and AKT and promoted the phosphorylated activation of AKT at S473, which could directly phosphorylate DRP1 at S637 to repress excessive mitochondrial fission. Consistently, the protective role of ATM was abolished by the AKT inhibitor MK-2206. Conclusions: Ataxia telangiectasia mutated protects against LPS-induced BBB disruption by regulating mitochondrial homeostasis, at least in part, through the AKT/DRP1 pathway.
参考来源
- Luo S, Lyu Z, Ge L, et al. ATAXIA TELANGIECTASIA MUTATED PROTECTS AGAINST LIPOPOLYSACCARIDE-INDUCED BLOOD-BRAIN BARRIER DISRUPTION BY REGULATING ATK/DRP1-MEDIATED MITOCHONDRIAL HOMEOSTASIS. Shock. 2023. PMID: 37141173. doi:10.1097/SHK.0000000000002139
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。